GT
ITCI

Glenmede Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Glenmede Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,877
Closed -$658K – 1453
2024
Q4 		$658K Sell
7,877
-3,592
-31% -$295K ﹤0.01% 838
2024
Q3 		$839K Sell
11,469
-1,289
-10% -$96.9K ﹤0.01% 770
2024
Q2 		$874K Buy
+12,758
New +$885K ﹤0.01% 729
2020
Q4 		– Sell
-99
Closed -$2K – 2321
2020
Q3 		$2K Buy
99
+55
+125% +$1.25K ﹤0.01% 2299
2020
Q2 		$1K Buy
+44
New +$891 ﹤0.01% 2392
2017
Q3 		– Sell
-19,410
Closed -$315K – 2860
2017
Q2 		$315K Hold
19,410
– – ﹤0.01% 1063
2017
Q1 		$315K Hold
19,410
– – ﹤0.01% 1063
2016
Q4 		$292K Buy
19,410
+11,762
+154% +$166K ﹤0.01% 1103
2016
Q3 		$116K Buy
+7,648
New +$309K ﹤0.01% 1359

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return